{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:06:48Z","timestamp":1786118808767,"version":"build-2736575974"},"reference-count":77,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1097\/mjt.0b013e31817fde95","type":"journal-article","created":{"date-parts":[[2008,12,17]],"date-time":"2008-12-17T03:14:39Z","timestamp":1229483679000},"page":"354-364","source":"Crossref","is-referenced-by-count":58,"title":["Appetite Suppressants, Cardiac Valve Disease and Combination Pharmacotherapy"],"prefix":"10.1097","volume":"16","author":[{"given":"Richard B","family":"Rothman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20210202","first-page":"985","article-title":"State-specific prevalence of obesity among adults-United States, 2005.","volume":"55","year":"2006","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R2-15-20210202","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1053\/j.gastro.2007.03.052","article-title":"The epidemiology of obesity.","volume":"132","author":"Ogden","year":"2007","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"R3-15-20210202","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.jada.2005.02.018","article-title":"Beyond energy balance: there is more to obesity than kilocalories.","volume":"105","author":"Bray","year":"2005","journal-title":"J Am Diet Assoc"},{"key":"R4-15-20210202","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/oby.2003.102","article-title":"A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity.","volume":"11","author":"Bray","year":"2003","journal-title":"Obes Res"},{"key":"R5-15-20210202","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/sj.ijo.0802741","article-title":"Weight cycling in treatment-seeking obese persons: data from the QUOVADIS study.","volume":"28","author":"Marchesini","year":"2004","journal-title":"Int J Obes Relat Metab Disord"},{"key":"R6-15-20210202","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/13548500600621545","article-title":"Effects of diets and their role in weight control.","volume":"12","author":"Amigo","year":"2007","journal-title":"Psychol Health Med"},{"key":"R7-15-20210202","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1056\/NEJMoa050156","article-title":"Randomized trial of lifestyle modification and pharmacotherapy for obesity.","volume":"353","author":"Wadden","year":"2005","journal-title":"N Engl J Med"},{"key":"R8-15-20210202","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1053\/j.gastro.2007.03.053","article-title":"Drug treatment of the overweight patient.","volume":"132","author":"Bray","year":"2007","journal-title":"Gastroenterology"},{"key":"R9-15-20210202","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1517\/13543784.15.3.257","article-title":"The potential use of selective 5-HT2C agonists in treating obesity.","volume":"15","author":"Smith","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"issue":"Suppl","key":"R10-15-20210202","doi-asserted-by":"crossref","first-page":"163S","DOI":"10.1038\/oby.2004.283","article-title":"Long-term pharmacotherapy for obesity.","volume":"12","author":"Klein","year":"2004","journal-title":"Obes Res"},{"key":"R11-15-20210202","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1146\/annurev.clinpsy.2.022305.095249","article-title":"Obesity.","volume":"2","author":"Fabricatore","year":"2006","journal-title":"AnnuRev Clin Psychol"},{"key":"R12-15-20210202","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nature05026","article-title":"Central nervous system control of food intake and body weight.","volume":"443","author":"Morton","year":"2006","journal-title":"Nature"},{"key":"R13-15-20210202","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jada.2005.03.010","article-title":"Medications as adjunct therapy for weight loss: approved and off-label agents in use.","volume":"105","author":"Moyers","year":"2005","journal-title":"J Am Diet Assoc"},{"key":"R14-15-20210202","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","article-title":"Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.","volume":"353","author":"Despres","year":"2005","journal-title":"N Engl J Med"},{"key":"R15-15-20210202","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/j.1550-8528.1999.tb00701.x","article-title":"Sibutramine produces dose-related weight loss.","volume":"7","author":"Bray","year":"1999","journal-title":"Obes Res"},{"key":"R16-15-20210202","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1037\/0022-006X.65.1.79","article-title":"What is a reasonable weight loss? Patients expectations and evaluations of obesity treatment outcomes.","volume":"65","author":"Foster","year":"1997","journal-title":"J Consult Clin Psychol"},{"key":"R17-15-20210202","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/clpt.1992.76","article-title":"Long-term weight control study: conclusions.","volume":"51","author":"Weintraub","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"R19-15-20210202","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/j.1550-8528.1997.tb00579.x","article-title":"Long-term drug treatment of obesity in a private practice setting.","volume":"5","author":"Atkinson","year":"1997","journal-title":"Obes Res"},{"key":"R20-15-20210202","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/j.1550-8528.1999.tb00414.x","article-title":"Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine.","volume":"7","author":"Ryan","year":"1999","journal-title":"Obes Res"},{"key":"R21-15-20210202","doi-asserted-by":"crossref","first-page":"896","DOI":"10.2337\/diacare.22.6.896","article-title":"Pharmacologic induction of weight loss to treat type 2 diabetes.","volume":"22","author":"Redmon","year":"1999","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"R22-15-20210202","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1524-6175.2007.08134.x","article-title":"Risk-based classification of hypertension and the role of combination therapy.","volume":"10","author":"Weir","year":"2008","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R23-15-20210202","first-page":"665","article-title":"Optimizing combination treatment in the management of type 2 diabetes.","volume":"3","author":"Derosa","year":"2007","journal-title":"Vasc Health Risk Manag"},{"key":"R24-15-20210202","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/1098-2299(200010)51:2<52::AID-DDR2>3.0.CO;2-H","article-title":"Neurochemical mechanisms of phentermine and fenfluramine: therapeutic and adverse effects.","volume":"51","author":"Rothman","year":"2000","journal-title":"Drug Dev Res"},{"key":"R25-15-20210202","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1749-6632.2002.tb04155.x","article-title":"Appetite suppressants as agonist substitution therapies for stimulant dependence.","volume":"965","author":"Rothman","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"R26-15-20210202","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nn1452","article-title":"How can drug addiction help us understand obesity?","volume":"8","author":"Volkow","year":"2005","journal-title":"Nat Neurosci"},{"key":"R28-15-20210202","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2174\/156802606778249766","article-title":"Therapeutic potential of monoamine transporter substrates.","volume":"6","author":"Rothman","year":"2006","journal-title":"Curr Top Med Chem"},{"key":"R29-15-20210202","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.tips.2006.10.006","article-title":"Dual dopamine-5-HT releasers: potential treatment agents for cocaine addiction.","volume":"27","author":"Rothman","year":"2006","journal-title":"Trends Pharmacol Sci"},{"key":"R30-15-20210202","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"key":"R31-15-20210202","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1146\/annurev.ne.16.030193.000445","article-title":"Neurotransmitter transporters: recent progress.","volume":"16","author":"Amara","year":"1993","journal-title":"Annu Rev Neurosci"},{"key":"R32-15-20210202","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0031-6997(24)01414-5","article-title":"Neurotransmitter transporters in the central nervous system.","volume":"51","author":"Masson","year":"1999","journal-title":"Pharmacol Rev"},{"key":"R33-15-20210202","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1242\/jeb.196.1.263","article-title":"Molecular physiology of norepinephrine and serotonin transporters [review].","volume":"196","author":"Blakely","year":"1994","journal-title":"J Exp Biol"},{"key":"R34-15-20210202","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1242\/jeb.196.1.229","article-title":"Neurotransmitter transporters: three important gene families for neuronal function.","volume":"196","author":"Uhl","year":"1994","journal-title":"J Exp Biol"},{"key":"R35-15-20210202","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0376-8716(98)00068-4","article-title":"Neurotransmitter transporters as molecular targets for addictive drugs.","volume":"51","author":"Amara","year":"1998","journal-title":"Drug Alcohol Depend"},{"key":"R36-15-20210202","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0005-2728(93)90109-S","article-title":"From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters [review].","volume":"1144","author":"Rudnick","year":"1993","journal-title":"Biochim Biophys Acta"},{"key":"R38-15-20210202","first-page":"225","article-title":"Biogenic amine neurotransmitter transporters: just when you thought you knew them.","volume":"20","author":"Blakely","year":"2005","journal-title":"Physiology (Bethesda)"},{"key":"R39-15-20210202","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ejphar.2003.08.072","article-title":"Oligomer formation by Na+-Cl-coupled neurotransmitter transporters.","volume":"479","author":"Sitte","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"R40-15-20210202","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.pneurobio.2005.04.003","article-title":"Mechanisms of neurotransmitter release by amphetamines: a review.","volume":"75","author":"Sulzer","year":"2005","journal-title":"Prog Neurobiol"},{"key":"R41-15-20210202","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2165\/00003495-197611050-00002","article-title":"Anorectic drugs: use in general practice.","volume":"11","author":"Craddock","year":"1976","journal-title":"Drugs"},{"key":"R42-15-20210202","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1124\/jpet.104.082503","article-title":"Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration.","volume":"313","author":"Rothman","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"R43-15-20210202","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/(SICI)1098-2396(200005)36:2<102::AID-SYN3>3.0.CO;2-#","article-title":"Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications.","volume":"36","author":"Baumann","year":"2000","journal-title":"Synapse"},{"key":"R44-15-20210202","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/syn.20126","article-title":"Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis.","volume":"56","author":"Alexander","year":"2005","journal-title":"Synapse"},{"issue":"Suppl 1","key":"R45-15-20210202","first-page":"80","article-title":"Assessment of reinforcing properties of amphetamine analogues in self-administering rats.","volume":"51","author":"Gotestam","year":"1975","journal-title":"Postgrad Med J"},{"key":"R46-15-20210202","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF00426841","article-title":"Comparison of behavior maintained by infusions of eight phenylethylamines in baboons.","volume":"50","author":"Griffiths","year":"1976","journal-title":"Psychopharmacology (Berl)"},{"key":"R47-15-20210202","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0022-5347(25)00192-2","article-title":"Amphetamine-like effects of anorectics and related compounds in pigeons.","volume":"241","author":"Evans","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"R48-15-20210202","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/BF00181948","article-title":"Substitution and cross-tolerance profiles of anorectic drugs in rats trained to detect the discriminative stimulus properties of cocaine.","volume":"95","author":"Wood","year":"1988","journal-title":"Psychopharmacology (Berl)"},{"key":"R49-15-20210202","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1021\/jm0305873","article-title":"Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters.","volume":"47","author":"Yu","year":"2004","journal-title":"J Med Chem"},{"key":"R50-15-20210202","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0146-2806(99)90013-0","article-title":"Obesity drugs and the heart.","volume":"24","author":"Connolly","year":"1999","journal-title":"Curr Probl Cardiol"},{"key":"R51-15-20210202","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0163-7258(02)00234-6","article-title":"Therapeutic and adverse actions of serotonin transporter substrates.","volume":"95","author":"Rothman","year":"2002","journal-title":"Pharmacol Ther"},{"issue":"Suppl","key":"R52-15-20210202","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0195-6663(86)80050-2","article-title":"Neurochemical mechanism of action of drugs which modify feeding via the serotoninergic system.","volume":"7","author":"Garattini","year":"1986","journal-title":"Appetite"},{"key":"R53-15-20210202","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0022-3565(24)37090-9","article-title":"In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor.","volume":"283","author":"Gundlah","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"R54-15-20210202","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0014-2999(02)01751-X","article-title":"Effects on serotonin in rat hypothalamus of D-fenfluramine, aminorex, phentermine and fluoxetine.","volume":"445","author":"Tao","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"R55-15-20210202","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF00547426","article-title":"Pharmacokinetics of fenfluramine and norfenfluramine in volunteers given D- and DL-fenfluramine for 15 days.","volume":"29","author":"Caccia","year":"1985","journal-title":"Eur J Clin Pharmacol"},{"key":"R56-15-20210202","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3109\/00498259209053154","article-title":"Comparative biodisposition and metabolism of 14C-(+\/-)-fenfluramine in mouse, rat, dog and man.","volume":"22","author":"Marchant","year":"1992","journal-title":"Xenobiotica"},{"key":"R57-15-20210202","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0014-2999(95)00300-A","article-title":"Studies of four novel diphenylbutylpiperazinepyridyl derivatives on release and inhibition of reuptake of dopamine, serotonin and noradrenaline by rat brain in vitro.","volume":"282","author":"Pettersson","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"R58-15-20210202","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0091-3057(97)00557-1","article-title":"Indian analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential.","volume":"59","author":"Cozzi","year":"1998","journal-title":"Pharmacol Biochem Behav"},{"key":"R59-15-20210202","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1124\/jpet.103.049684","article-title":"(+)-fenfluramine and its major metabolite, (+)-norfenfluramine, are potent substrates for norepinephrine transporters.","volume":"305","author":"Rothman","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R60-15-20210202","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0014-2999(00)00216-8","article-title":"Enantioselective behavioral effects of sibutramine metabolites.","volume":"397","author":"Glick","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"R61-15-20210202","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1067\/mhj.2002.126733","article-title":"Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies.","volume":"144","author":"Sachdev","year":"2002","journal-title":"Am Heart J"},{"key":"R62-15-20210202","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine.","volume":"337","author":"Connolly","year":"1997","journal-title":"N Engl J Med"},{"key":"R63-15-20210202","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/335254a0","article-title":"Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein.","volume":"335","author":"Seuwen","year":"1988","journal-title":"Nature"},{"key":"R64-15-20210202","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF00614199","article-title":"Pharmacokinetics of methysergide and its metabolite methylergometrine in man.","volume":"30","author":"Bredberg","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"R65-15-20210202","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/0002-8703(74)90251-8","article-title":"Cardiac murmurs and endocardial fibrosis associated with methysergide therapy.","volume":"88","author":"Bana","year":"1974","journal-title":"Am Heart J"},{"key":"R66-15-20210202","first-page":"235","article-title":"Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature.","volume":"5","author":"Hendrikx","year":"1996","journal-title":"J Heart Valve Dis"},{"key":"R67-15-20210202","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0031-6997(25)06783-3","article-title":"International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).","volume":"46","author":"Hoyer","year":"1994","journal-title":"Pharmacol Rev"},{"key":"R68-15-20210202","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0893-133X(00)00221-9","article-title":"1-(m-Chlorophenyl)piperazine (mCPP) dissociates in vivo serotonin release from long-term serotonin depletion in rat brain.","volume":"24","author":"Baumann","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"R69-15-20210202","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1517\/17425255.1.3.377","article-title":"Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on fen-phen.","volume":"1","author":"Setola","year":"2005","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R70-15-20210202","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0026-895X(24)26444-0","article-title":"Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine.","volume":"57","author":"Fitzgerald","year":"2000","journal-title":"Mol Pharmacol"},{"key":"R71-15-20210202","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.bjp.0702751","article-title":"Functional characterization of agonists at recombinant human 5-HT2A, 5- HT2B and 5-HT2C receptors in CHO-K1 cells.","volume":"128","author":"Porter","year":"1999","journal-title":"Br J Pharmacol"},{"key":"R72-15-20210202","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0006-2952(98)00059-8","article-title":"Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades.","volume":"56","author":"Lopez-Ilasaca","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"R73-15-20210202","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s002280050391","article-title":"Correlation between steady-state plasma concentrations of mianserin and trazodone in depressed patients.","volume":"53","author":"Otani","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"R74-15-20210202","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1124\/mol.63.6.1223","article-title":"3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.","volume":"63","author":"Setola","year":"2003","journal-title":"Mol Pharmacol"},{"key":"R75-15-20210202","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.amjcard.2007.06.045","article-title":"Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease.","volume":"100","author":"Droogmans","year":"2007","journal-title":"Am J Cardiol"},{"key":"R76-15-20210202","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp068265","article-title":"Drugs and valvular heart disease.","volume":"356","author":"Roth","year":"2007","journal-title":"N Engl J Med"},{"key":"R77-15-20210202","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1124\/jpet.107.133348","article-title":"Lorcaserin, a novel selective human 5-HT2C agonist: in vitro and in vivo pharmacological characterization.","volume":"325","author":"Thomsen","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"R78-15-20210202","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00003495-200767010-00004","article-title":"Serotonergic drugs: effects on appetite expression and use for the treatment of obesity.","volume":"67","author":"Halford","year":"2007","journal-title":"Drugs"},{"key":"R80-15-20210202","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJM199708283370909","article-title":"Diet Pills Redux.","volume":"337","author":"Curfman","year":"1997","journal-title":"N Engl J Med"},{"key":"R81-15-20210202","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJM199809103391109","article-title":"Appetite suppressants and valvular heart disease.","volume":"339","author":"Devereux","year":"1998","journal-title":"N Engl J Med"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MJT.0b013e31817fde95","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:45:50Z","timestamp":1786034750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045391-200907000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e31817fde95","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}